Beginning a PhD is rarely straightforward. Beginning one just as the world shuts down adds an entirely new dimension to adaptability. For George Mason University biosciences PhD student Matthew Lefkowitz, that quality would come to define his doctoral journey.

Cure CMD announces its selection as an Official Charity Partner of the 2026 TCS New York City Marathon and introduces Team Cure CMD.

Ashley Burkman shares how testifying for Medicaid highlighted the daily reality of CMD caregiving and how honest storytelling can drive advocacy and change.

Cure CMD shares an important research update regarding Dr. Carsten Bönnemann’s move to St. Jude Children’s Research Hospital and ongoing CMD research at the National Institutes of Health led by Dr. Reghan Foley.

Cure CMD is proud to partner with the Muscular Dystrophy Association and Cure ADSSL1 to support groundbreaking research at the Beggs Laboratory at Boston Children’s Hospital. This collaborative project will use next-generation genomic tools and AAV-based gene therapies to better understand disease mechanisms and advance potential treatments for SELENON-Related Myopathy, demonstrating how partnership across the rare disease community can accelerate progress toward meaningful t

Cure CMD joined rare disease advocates in Washington, DC for Rare Disease Week 2026, meeting with lawmakers to raise awareness of congenital muscular dystrophy and the urgent need for research support.

Researchers at the University of Basel are developing a gene therapy that could potentially treat those living with LAMA2-Related Dystrophy.